Safety and Efficacy of 333369 in the Treatment of Partial Epilepsy
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the efficacy, safety, and tolerability of
4 daily doses of RWJ-333369 as adjunctive treatment of refractory partial epilepsy in
subjects who are between 18 and 70 years of age, inclusive